Science & Enterprise subscription

Please share Science & Enterprise

RSS
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Start-Up to Tackle Neurodegenerative Diseases, Raises $31 Million

Magnolia Neuroscience

A new company is forming to develop treatments that protect against destruction of brain cells in Alzheimer’s disease and comparable nerve damage from chemotherapy. . . . → Read More: Start-Up to Tackle Neurodegenerative Diseases, Raises $31 Million

Infographic – U.S. Falling Way Behind on 5G

5G development

The success of mobile devices depends on their underlying technologies, with the next generation of mobile standards known as 5G in the queue. . . . → Read More: Infographic – U.S. Falling Way Behind on 5G

Start-Up Developing Regenerative Liver Disease Treatments

Damaged liver cells

A new enterprise founded by scientists, is underway developing treatments for advanced liver disorders that combine new drugs with cell and gene therapies to restore or replace liver functions. . . . → Read More: Start-Up Developing Regenerative Liver Disease Treatments

Biotechs Partner on Antibody, T-Cell Cancer Therapies in $100M Deal

T-cells illustration

Two biotechnology companies with complementary technologies plan to create treatments for cancer that harness and modify cells from the immune system delivered with benign viruses. . . . → Read More: Biotechs Partner on Antibody, T-Cell Cancer Therapies in $100M Deal

Infographic – Harvard or Stanford? Venture Capitalists Revealed.

Venture capitalist demographics

Our reporting on venture capital, much like other business media, tells about the companies investing in early-stage enterprises, but what about the people in the industry? . . . → Read More: Infographic – Harvard or Stanford? Venture Capitalists Revealed.

Univ. Spin-Off Developing Myelin Disease Treatments Unveiled

Neurons

A spin-off enterprise from Case Western Reserve University is developing therapies designed to restore the myelin sheath around nerve cells destroyed in multiple sclerosis and other neurological disorders. . . . → Read More: Univ. Spin-Off Developing Myelin Disease Treatments Unveiled

GSK, 23andMe Ink Precision Meds Discovery Deal

Saliva sample kit

Consumer genetics company 23andMe signed a 4-year agreement to help drug maker GlaxoSmithKline find more precise drug targets and recruit clinical trial participants likely to respond to treatments. . . . → Read More: GSK, 23andMe Ink Precision Meds Discovery Deal

Gates, Lauder Backing Early Alzheimer’s Biomarker Tests

Brain circuits

A group of well-known philanthropists is backing a new research program to find simple tests that reveal early indicators of Alzheimer’s disease in a person’s molecular make-up. . . . → Read More: Gates, Lauder Backing Early Alzheimer’s Biomarker Tests

A.I. Drug Discovery Company Gains $32M in Early Funds

Brain hemispheres graphic

A company using genomic databases and artificial intelligence to discover new therapies for neurodegenerative diseases is raising $32 million in its first venture funding round. . . . → Read More: A.I. Drug Discovery Company Gains $32M in Early Funds

New $315 Million Life Sciences Venture Fund Unveiled

Investment graphic

A life science and health care investment company in the U.K. today revealed its 12th venture capital fund for start-up and current enterprises in the U.S. and Europe. . . . → Read More: New $315 Million Life Sciences Venture Fund Unveiled